BNC Korea Co., Ltd. (KOSDAQ:A256840) agreed to acquire a 63.2% stake in Dong-in Biotech Co., Ltd. from Jo Gil-nam and others for KRW 12 billion on May 13, 2022. As part of the transaction, BNC Korea will acquire 44,210 shares in Dong-in Biotech. As of the date, Jo Gil-nam holds 37.43% stake in Dong-in Biotech. For the year ended December 31, 2021, Dong-in Biotech reported Total assets of KRW 16.309 billion, Total Debt of KRW 5.948 billion, total equity of KRW 10.361 billion, revenue of KRW 27.711 billion and Net Income of KRW 1.848 billion. The transaction is resolved by the board of BNC Korea and expected to complete on July 18, 2022.